Solubility enhancing lipid-based vehicles for artemether and lumefantrine destined for the possible treatment of induced malaria and inflammation: in vitro and in vivo evaluations

Beni-Suef University Journal of Basic and Applied Sciences

Table 9 Effects of Artemether and Lumefantrine loaded LSES on white blood cell differentials

Groups	White blood cell differentials (mean ± SD)
Groups	Lymphocytes (%)	Neutrophils (%)	Monocytes (%)	Eosinoph (%)
Group 1	70.75 ± 4.82	23.00 ± 4.20	5.50 ± 0.96	1.00 ± 0.41
Group 2	75.00 ± 4.65	21.50 ± 4.79	3.00 ± 0.00	0.50 ± 0.50
Group 3	73.75 ± 1.31	22.25 ± 2.46	2.75 ± 0.85	0.75 ± 0.48
Group 4	73.25 ± 4.94	19.75 ± 3.97	4.25 ± 1.03	2.75 ± 0.85
Group 5	66.50 ± 5.25	29.00 ± 5.69	3.50 ± 0.95	1.50 ± 0.95
Group 6	67.00 ± 6.61	32.00 ± 5.94	5.50 ± 0.50	2.00 ± 0.82
Group 7	68.00 ± 6.94	26.50 ± 6.02	4.25 ± 1.18	1.25 ± 0.75
Group 8	67.25 ± 3.54	24.75 ± 2.56	5.50 ± 0.87	2.50 ± 1.26
Group 9	69.50 ± 3.20	20.50 ± 0.96	6.50 ± 0.96	3.00 ± 1.29

Results are expressed in Means ± SD (n = 5)
Group 1—SRBC + distilled water; Group 2—SRBC + diluent only; Group 3—SRBC + commercial drug sample (40 mg/kg); Group 4—SRBC + Artemether + Lumefantrin solution (40 mg/kg); Group 5—SRBC + Artemether solution (40 mg/kg); Group 6—SRBC + Lumefantrin solution (40 mg/kg); Group 7—SRBC + Artemether + Lumefantrin formulation (40 mg/kg); Group 8—SRBC + Artemether formulation (40 mg/kg); Group 9—SRBC + Lumefantrin formulation (40 mg/kg)